Skip directly to page options Skip directly to A-Z link
Volume 30, Number 1—January 2024
Research

Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018–2021

Ntwali Placide Nsengiyumva, Amera Khan, Maricelle Ma. Tarcela S. Gler, Mariecef L. Tonquin, Danaida Marcelo, Mark C. Andrews, Karine Duverger, Shahriar Ahmed, Tasmia Ibrahim, Sayera Banu, Sonia Sultana, Mona Lisa Morales, Andre Villanueva, Egwumo Efo, Baraka Onjare, Cristina Celan, and Kevin SchwartzmanComments to Author 
Author affiliations: McGill International Tuberculosis Centre and Research Institute, McGill University Health Centre, Montreal, Quebec, Canada (N.P. Nsengiyumva, K. Schwartzman); Stop TB Partnership, Geneva, Switzerland (A. Khan); De La Salle Medical and Health Sciences Institute, Makati City, Philippines (M.M.T.S. Gler, M.L. Tonquin, D. Marcelo); Health Through Walls, Port au Prince, Haiti (M.C. Andrews, K. Duverger); icddr,b, Dhaka, Bangladesh (S. Ahmed, T. Ibrahim, S. Banu, S. Sultana); KNCV, Manila, Philippines (M.L. Morales, A. Villanueva); KNCV, Dar es Salaam, Tanzania (E. Efo, B. Onjare); Center for Health Policies and Studies, Chisinau, Moldova (C. Celan)

Main Article

Figure 2

Video-observed tuberculosis therapy scale-up scenario analysis for 3 countries: A) Haiti; B) Moldova; C) the Philippines. In each scenario, fixed technology/platform introduction and maintenance costs are shared across expanded user numbers (i.e., 2× study population, 5× study population, 10× study population, and 100× study population) while maintaining the same variable costs. All TB, all TB patients; DR-TB, drug-resistant TB; DS-TB, drug-susceptible TB; TB, tuberculosis.

Figure 2. Video-observed tuberculosis therapy scale-up scenario analysis for 3 countries: A) Haiti; B) Moldova; C) the Philippines. In each scenario, fixed technology/platform introduction and maintenance costs are shared across expanded user numbers (i.e., 2× study population, 5× study population, 10× study population, and 100× study population) while maintaining the same variable costs. All TB, all TB patients; DR-TB, drug-resistant TB; DS-TB, drug-susceptible TB; TB, tuberculosis.

Download

Main Article

Page created: October 31, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external